1-13 of 13
Valerie M. Jansen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

Matthew P. Goetz, Erika P. Hamilton, Mario Campone, Sara A. Hurvitz, Javier Cortes, Stephen Johnston, Antonio Llombart-Cussac, Peter A. Kaufman, Masakazu Toi, Guy Jerusalem, Hillary Graham, Hong Wang, Valerie M. Jansen, Lacey M. Litchfield, Miguel Martin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2233–2244.
https://doi.org/10.1158/1078-0432.CCR-22-3573
Published: 15 May 2024
View article titled, Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Open the PDF for Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4587.
https://doi.org/10.1158/1078-0432.CCR-22-2874
Published: 14 October 2022
View article titled, Correction: Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Open the PDF for Correction: Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant in another window
Journal Articles

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1500–1506.
https://doi.org/10.1158/1078-0432.CCR-21-3276
Published: 14 April 2022
View article titled, Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Open the PDF for Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant in another window
Includes: Supplementary data
Journal Articles

Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4939.
https://doi.org/10.1158/1078-0432.CCR-21-2431
Published: 01 September 2021
View article titled, Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Journal Articles

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4870–4882.
https://doi.org/10.1158/1078-0432.CCR-19-4191
Published: 01 September 2021
View article titled, Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Margaret L. Axelrod, Mellissa J. Nixon, Paula I. Gonzalez-Ericsson, Riley E. Bergman, Mark A. Pilkinton, Wyatt J. McDonnell, Violeta Sanchez, Susan R. Opalenik, Sherene Loi, Jing Zhou, Sean Mackay, Brent N. Rexer, Vandana G. Abramson, Valerie M. Jansen, Simon Mallal, Joshua Donaldson, Sara M. Tolaney, Ian E. Krop, Ana C. Garrido-Castro, Jonathan D. Marotti, Kevin Shee, Todd W. Miller, Melinda E. Sanders, Ingrid A. Mayer, Roberto Salgado, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5668–5681.
https://doi.org/10.1158/1078-0432.CCR-19-3685
Published: 02 November 2020
View article titled, Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Open the PDF for Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

Sara A. Hurvitz, Miguel Martin, Michael F. Press, David Chan, María Fernandez-Abad, Edgar Petru, Regan Rostorfer, Valentina Guarneri, Chiun-Sheng Huang, Susana Barriga, Sameera Wijayawardana, Manisha Brahmachary, Philip J. Ebert, Anwar Hossain, Jiangang Liu, Adam Abel, Amit Aggarwal, Valerie M. Jansen, Dennis J. Slamon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (3): 566–580.
https://doi.org/10.1158/1078-0432.CCR-19-1425
Published: 03 February 2020
View article titled, Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Open the PDF for Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

Luigi Formisano, Kimberly M. Stauffer, Christian D. Young, Neil E. Bhola, Angel L. Guerrero-Zotano, Valerie M. Jansen, Mónica M. Estrada, Katherine E. Hutchinson, Jennifer M. Giltnane, Luis J. Schwarz, Yao Lu, Justin M. Balko, Olivier Deas, Stefano Cairo, Jean-Gabriel Judde, Ingrid A. Mayer, Melinda Sanders, Teresa C. Dugger, Roberto Bianco, Thomas Stricker, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1433.
https://doi.org/10.1158/1078-0432.CCR-18-4268
Published: 15 February 2019
View article titled, Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer
Open the PDF for Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer in another window
Journal Articles

Correction: Is There a Future for AKT Inhibitors in the Treatment of Cancer?

Valerie M. Jansen, Ingrid A. Mayer, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1436.
https://doi.org/10.1158/1078-0432.CCR-18-4265
Published: 15 February 2019
View article titled, Correction: Is There a Future for AKT Inhibitors in the Treatment of Cancer?
Open the PDF for Correction: Is There a Future for AKT Inhibitors in the Treatment of Cancer? in another window
Journal Articles

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1431.
https://doi.org/10.1158/1078-0432.CCR-18-4270
Published: 15 February 2019
View article titled, Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Open the PDF for Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors in another window
Journal Articles

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2517–2529.
https://doi.org/10.1158/1078-0432.CCR-17-2904
Published: 31 May 2018
View article titled, ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Open the PDF for ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors in another window
Includes: Supplementary data
Journal Articles

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

Luigi Formisano, Kimberly M. Stauffer, Christian D. Young, Neil E. Bhola, Angel L. Guerrero-Zotano, Valerie M. Jansen, Mónica M. Estrada, Katherine E. Hutchinson, Jennifer M. Giltnane, Luis J. Schwarz, Yao Lu, Justin M. Balko, Olivier Deas, Stefano Cairo, Jean-Gabriel Judde, Ingrid A. Mayer, Melinda Sanders, Teresa C. Dugger, Roberto Bianco, Thomas Stricker, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6138–6150.
https://doi.org/10.1158/1078-0432.CCR-17-1232
Published: 12 October 2017
View article titled, Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer
Open the PDF for Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Is There a Future for AKT Inhibitors in the Treatment of Cancer?

Valerie M. Jansen, Ingrid A. Mayer, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2599–2601.
https://doi.org/10.1158/1078-0432.CCR-16-0100
Published: 31 May 2016
View article titled, Is There a Future for AKT Inhibitors in the Treatment of Cancer?
Open the PDF for Is There a Future for AKT Inhibitors in the Treatment of Cancer? in another window